Lilly shuffles top team as diabetes, obesity leader to retire

2023-10-04

高管变更

Eli Lilly announced Wednesday that Mike Mason, who currently serves as president of the company’s diabetes and obesity unit, will retire at the end of the year. The drugmaker said that Patrik Jonsson will assume leadership of the diabetes and obesity segment, in addition to his current position as president of Lilly USA.

Other changes at Eli Lilly will see Daniel Skovronsky - the company’s chief scientific officer and president of Lilly Research Laboratories - take on the additional role of president of immunology from Jonsson. Meanwhile, David Hyman will become Eli Lilly's chief medical officer, in addition to continuing to oversee oncology development, with Mark Genovese joining from Gilead Sciences on October 16 to lead clinical development of the mid and late-stage immunology portfolio.

Further, Eli Lilly noted that Leigh Ann Pusey, executive vice president of corporate affairs and communications, has decided to leave the company at the end of 2023 for another career opportunity.

More to come.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构